RASSF4 can serve as a biomarker for indicating MASLD disease progression and assessing HCC prognosis, and its associated pathways may provide new targets for targeted therapy in liver fibrosis and HCC [27,36]. This evidence concerns the gene RASSF4 and hepatocellular carcinoma.